DORNASE ALPHA: THREE CLINICAL EFFECTS
Chronic diseases of lungs are characterized by the presence of mucostasis which is the reason for often aggravations of bron chopulmonary process and favors progression of the disease. The article convincingly shows the necessity of inclusion mucolytic therapy in baseline therapy in the treatment of...
Saved in:
Main Author: | O.I. Simonova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Union of pediatricians of Russia
2008-03-01
|
Series: | Педиатрическая фармакология |
Online Access: | https://www.pedpharma.ru/jour/article/view/872 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
DORNASE ALFA: WHAT EFFECTIVENESS OF MEDICATION DEPENDS ON?
by: O.I. Simonova
Published: (2009-07-01) -
OPPORTUNITIES OF DORNASE ALFA IN PEDIATRICS
by: O.I. Simonova
Published: (2011-07-01) -
AN IMPORTANT COMPONENT OF BASIC THERAPY IN CYSTIC FIBROSIS (MUCOVYSCIDOSIS) IN CHILDREN: DORNASE ALFA
by: O.I. Simonova
Published: (2011-10-01) -
PECULIARITIES OF DORNASE ALFA AND KINESITHERAPY USE IN CHILDREN WITH CYSTIC FIBROSIS
by: O. I. Simonova
Published: (2013-07-01) -
A MUCOLYTIC WITH ANTIINFLAMMATORY QUALITIES FOR CHILDREN SUFFERED FROM CYSTIC FIBROSIS: DORNASE ALFA
by: O. I. Simonova, et al.
Published: (2012-12-01)